How do small biotechs bursting with innovation leverage the toolbox of big pharma?
Enter Allucent, led by CEO Paula Brown Stafford, who are turbocharging drug developers worldwide!
Onyx Studio Sessions: Paula Brown Stafford, CEO, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Related
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?